[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vertebral-artery-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vertebral-artery-stenosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,65,89,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100362498","vertebral-artery-origin-treatment-via-endovascular-techniques-registry-voter-100362498",false,"NCT03999983","Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)","VOTER","Inclusion Criteria:\n\n1. Patients between 18 and 90 years of age\n2. Patient has experienced a posterior circulation ischemic event\n3. Patient has angiographically confirmed bilateral vertebral artery origin disease (Hypoplasia, occlusion, or stenosis).\n4. Patient has \\>50% stenosis on the side being targeted for therapy\n\nExclusion Criteria:\n\n1. Pregnant women\n2. Contrast Indication to the use of anti-platelet drugs\n3. There is tandem vertebral or basilar artery stenosis\n4. The serum creatinin is \\>2.5\n5. Baseline modified Rankin score is \\>3\n6. \\\u003C 5 years life expectancy","ALL","18 Years","90 Years",{"count":20,"type":21},150,"ESTIMATED","1 Year","OBSERVATIONAL","A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).",[26],"Vertebral Artery Stenosis","RECRUITING","2025-02-10",{"date":30,"type":31},"2025-02-12","ACTUAL",{"date":33,"type":31},"2019-11-19",{"date":35,"type":21},"2026-12",{"name":37,"class":38},"St. Louis University","OTHER",10,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":62,"locationsCount":64},"100568597","drug-eluting-stenting-and-short-dual-antiplatelet-therapy-for-preventing-recurrent-stroke-in-vertebral-stenosis-registry-study-100568597","NCT06683300","Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study","M Short DAPT","Inclusion Criteria:\n\n1. Age ≥18 years old, gender unlimited;\n2. Based on clinical and imaging evidence, the investigators identified patients with symptomatic vertebral atherosclerotic stenosis who met the indications for the placement of drug-eluting vertebral artery stents;\n3. Patients or their guardians sign informed consent.\n\nExclusion Criteria:\n\n1. Severe coagulation dysfunction, serious uncontrolled infection, serious systemic disease, uncontrolled hypertension, etc., are not suitable for surgery;\n2. Patients with aneurysms that cannot be treated in advance or at the same time or are not suitable for surgery;\n3. Myocardial infarction or large-scale cerebral infarction occurred within 2 weeks;\n4. Combined with atrial fibrillation, or accompanied by serious heart, liver, kidney and lung diseases;\n5. Interventional or surgical procedures are planned within 90 days;\n6. Known contraindications to heparin, rapamycin, anesthesia and contrast agents;\n7. Life expectancy is less than 12 months;\n8. The researcher considers it inappropriate to participate in this study.",{"count":48,"type":21},520,"This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis. The trial will be conducted in approximately 30 interventional neurology centers in China.\n\nCurrently, there is no consensus regarding the duration of DAPT after drug-eluting stent treatment for vertebral artery stenosis(VAS). The objective of this study is to standardize clinical medication by shortening the duration of DAPT, thereby reducing the bleeding risk and medication burden for patients, while ensuring that there is no increase in ischemic events.",[26],[52,53,54],"vertebral artery stent","dual antiplatelet duration","symptomatic vertebral artery atherosclerotic stenosis","NOT_YET_RECRUITING","2024-11-08",{"date":58,"type":31},"2024-11-12",{"date":60,"type":21},"2024-11",{"date":35,"type":21},{"name":63,"class":38},"Beijing Tiantan Hospital",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":64},"100539279","a-prospective-experimental-multicenter-open-label-randomized-controlled-trial-of-3-month-dual-antiplatelet-therapy-followed-by-ticagrelor-versus-6-month-dual-antiplatelet-therapy-followed-by-ticagrelor-after-implanting-bridge-100539279","NCT06301776","A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge","Inclusion Criteria:\n\n* Patients who are suitable for Bridge implantation\n* Symptomatic vertebral artery stenosis with a history of posterior circulation-related ischaemic stroke or TIA despite the use of at least one antithrombotic medications and intervention for risk factors\n* Responsible vertebral artery stenosis (≥70% stenosis, measured by the NASCET method ) confirmed by DSA imaging\n* The patient and\u002For his\u002Fher authorised person understands the purpose of the study, agrees to participate in the study and signs the informed consent form\n\nExclusion Criteria:\n\n* mRS≥3\n* Presence of tandem stenotic lesions in the target lesion areaor combined basilar artery stenosis Presence of ≥2 stenotic cerebrovascular lesions requiring concurrent intervention The presence of severe tortuosity or calcification of the target vessel, or the presence of extensive abnormal vascular structural variants that are difficult for catheters or stents to pass or cannot be implanted\n* Lesions or stenosis that is too large and beyond the specification of the stent\n* Non-atherosclerotic stenosis such as atrial fibrillation, vasculitis stenosis, arterial entrapment, smoky disease, active phase of arteritis, or unknown cause\n* Contraindication to heparin, aspirin, tegretol, clopidogrel, or other antiplatelet drugs, and those who cannot tolerate anticoagulant and antiplatelet drug therapy\n* Have had intracranial haemorrhage within 3 months\n* Had a myocardial infarction or large cerebral infarction within 2 weeks\n* Accompanied by other intracranial disease such as aneurysm, arteriovenous malformation, intracranial tumour, intracranial infection, etc\n* Presence of active bleeding or extremely dangerous risk of haemorrhage (e.g. active peptic ulcer disease, gastrointestinal lesions with bleeding risk, malignant tumours with bleeding risk, etc.)\n* Severe cardiac, hepatic, splenic, pulmonary, or renal impairment, or allergy or intolerance to contrast media, rapamycin (Rapamycin) and its derivatives, cobalt-based alloys, or polylactic acid","80 Years",{"count":73,"type":21},560,"INTERVENTIONAL",[76],"NA","To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral artery stenosis in subjects who had been taking different durations of dual-antiplatelet therapy (3 vs 6 months) and ticagrelor monotherapy.",[79,26],"Brain Disease","2024-03-04",{"date":82,"type":31},"2024-03-08",{"date":84,"type":31},"2023-12-05",{"date":86,"type":21},"2026-06-30",{"name":88,"class":38},"The Fourth Affiliated Hospital of China Medical University",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":74,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":64},"100507326","drug-eluting-stenting-versus-medical-treatment-for-extracranial-vertebral-artery-stenosis-100507326","NCT05885932","Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis","Drug-eluting Stenting Versus Medical Treatment Alone for Patients With Extracranial Vertebral Artery Stenosis: The VISTA Trial","VISTA","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Extracranial vertebral artery (V1-2 segments) has 70% to 99% stenosis (NASCET criteria by angiography), and the diameter of the target vessel ≥ 2.5mm.\n3. History of clinical symptoms associated with target vessels within 3 months before randomization, including ischemic stroke (modified Rankin Scale, mRS score ≤ 3) or transient ischemic attack (TIA).\n4. With more than two atherosclerotic risk factors such as, hypertension, hyperlipidemia, diabetes, smoking, drinking, obesity, or obstructive sleep apnea (following the 2021 AHA\u002FASA guidelines).\n5. mRS score ≤ 3.\n6. Patients or their guardians voluntarily participate of the study and sign the consent form.\n\nExclusion Criteria:\n\n1. Vertebral artery stenosis caused by non-atherosclerotic lesions, including arterial dissection, Moyamoya disease, vasculitis disease, radiation-induced vascular disease, fibromuscular dysplasia, etc.\n2. Tandem extracranial or intracranial severe stenosis or occlusion of the target vessel.\n3. History of open surgery or endovascular treatment of the target vessel.\n4. Other cerebrovascular diseases that require one-stage open surgery or endovascular therapies.\n5. Open surgery or endovascular treatment for other cerebrovascular diseases within 1 month.\n6. Patients in whom vertebral anatomy was felt to be technically not feasible for vertebral artery stenting (e.g. access problems).\n7. The contralateral vertebral artery and basilar artery have lesions that may be related to the symptoms, and the investigators cannot confirm that the target vessel is the responsible vessel for the symptoms (For example, the ostium of bilateral vertebral artery is severely narrowing, and the diameter of vertebral artery is equal, unable to determine the dominant vertebral artery).\n8. Known allergy or contraindication to iodinated contrast media and sirolimus.\n9. History of acute ischemic stroke within 7 days.\n10. History of intracranial hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, or extradural hemorrhage within 6 weeks.\n11. Cardioembolic strokes as evident by prior history of strokes in other territories or multi-territory strokes in the presence of risk factors known to be associated with cardiogenic embolism (e.g. atrial fibrillation, left ventricular thrombus or history of myocardial infarction within 6 weeks, etc.).\n12. Coagulation dysfunction or hemorrhagic tendency (e.g. INR \\> 1.5 and\u002For platelet count \\\u003C 100×10\\^9\u002FL).\n13. Cannot complete the follow-up due to severe diseases (e.g. serious infections, severe chronic obstructive pulmonary disease, malignancy, dementia, mental illness, uncontrolled server hypertension or diabetes).\n14. Women who are pregnant or lactating.\n15. According to the judgement of the investigator, other situations, influencing the safety and efficacy evaluation, which make the patient not suitable for enrollment.",{"count":98,"type":21},472,[76],"Posterior circulation stroke accounts for 20% of all ischemic stroke. Approximately one quarter of posterior circulation strokes are due to stenosis in the vertebral artery and basilar artery.\n\nTwo previous randomized controlled trials focusing on vertebral artery stenting, the Vertebral Artery Stenting Trial (VAST) and the Vertebral Artery Ischaemia Stenting Trial (VIST) were underpowered because they failed to reach target recruitment, and both the trials found no difference in risk of the primary outcome between the stenting group and medical group.\n\nThe drug-eluting stenting versus medical therapy alone for patients with extracranial vertebral artery stenosis (VISTA) trial, is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit patients with 3 months stroke or TIA caused by 70-99% stenosis of extracranial vertebral artery (V1-2 segments). Only high-volume center with a proven track record will enroll patients. Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus stenting. Primary outcome is a composite of any fatal or non-fatal stroke within 30 days after randomization, or ischemic stroke in the territory of the target artery beyond 30 days to 1 year. The VISTA trial will be conducted in 30 sites in China and aims to have a sample size of 472 subjects (stenting, 236; medical treatment, 236). Recruitment is expected to be finished by Sep, 2025. Patients will be followed for 1 year at first stage. Long-term follow-ups till 3 years or longer is also preplanned. The first stage of the trial is scheduled to complete in 2027.",[102,26],"Ischemic Stroke",[104,105,106,107],"Extracranial vertebral artery stenosis","Drug-eluting stenting","Best medical treatment","Ischemic stroke","2023-09-15",{"date":110,"type":31},"2023-09-21",{"date":112,"type":31},"2023-08-25",{"date":114,"type":21},"2028-09",{"name":116,"class":38},"Xuanwu Hospital, Beijing",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":74,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":64},"100488761","efficacy-of-drug-eluting-vertebral-artery-stenting-treatment-for-atherosclerotic-vertebral-arteries-stenosis-100488761","NCT05644314","Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis","Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender is not limited;\n2. Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;\n3. Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery;\n2. With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery;\n3. Gastrointestinal disease with active bleeding;\n4. Previous myocardial infarction or large-scale cerebral infarction within 2 weeks;\n5. Known contraindications to heparin, rapamycin, anesthesia, and contrast agents;\n6. Life expectancy less than 12 months;\n7. the investigator judged patients to be unsuitable for participation in this study.",{"count":125,"type":21},144,[76],"This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.",[102,26],"2023-03-13",{"date":131,"type":31},"2023-03-14",{"date":133,"type":31},"2022-05-01",{"date":135,"type":21},"2029-05-31",{"name":137,"class":38},"Nanfang Hospital, Southern Medical University"]